Early results from an ongoing phase 1/2 clinical trial show promising activity for vopimetostat, an oral PRMT5 inhibitor, when combined with RAS-targeted therapies in patients with advanced, previously treated pancreatic cancer that has an MTAP deletion.
The strongest results were seen with vopimetostat plus daraxonrasib in patients with RAS-mutant pancreatic cancer. Among 12 evaluable patients, 92% experienced tumor shrinkage meeting the criteria for an objective response, and all patients achieved disease control. After six months, 90% remained free from disease progression, and the median progression-free survival has not yet been reached.
In patients with both MTAP deletion and a KRAS G12D mutation, the combination of vopimetostat and zoldonrasib produced a 52% response rate and a 96% disease control rate. The six-month progression-free survival rate was 74%.
As of May 2026, 59 patients had been treated. Most had aggressive disease, including liver metastases, and many had already received multiple prior treatments. Both combinations were generally well tolerated, suggesting they could offer an effective chemotherapy-free treatment option for some patients with advanced pancreatic cancer.